Duration of Platelet Inhibition by Aspirin
The well established importance of regular aspirin administration stands on firm grounds, as large meta-analyses have shown this therapy to significantly reduce the risk of death. However, not all patients benefit of aspirin administration to the same extent, thus high-lighting a sub-population of patients with inadequate platelet response to ASA. The mechanisms underlying reduced ASA efficacy remain elusive. A recent report has suggested that platelets, long believed to be incapable of de novo protein synthesis, may retain their ability to form the cyclooxygenase enzyme, once it has been inactivated by aspirin. This may explain the inefficacy of the drug to induce sustained platelet inhibition in certain patients.
The current study aims to evaluate, in patients suffering from stable coronary artery disease, the stability of platelet inhibition by aspirin during the normal once daily dosing regimen.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Evaluation of Duration of Platelet Inhibition by Aspirin in a Standard 24-hour Interval Dosing Regimen|
- Platelet aggregation TxA2 formation
|Study Start Date:||July 2008|
|Study Completion Date:||January 2009|
|Primary Completion Date:||January 2009 (Final data collection date for primary outcome measure)|
Patients suffering from stable CAD, on chronic ASA therapy
Other: Platelet aggregation
Platelet aggregation TxA2 formation
|Hôpital du Sacré-Coeur de Montréal|
|Montreal, Quebec, Canada, H4J 1C5|
|Principal Investigator:||Jean G Diodati, MD||Hopital du Sacre-Coeur de Montreal|